During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with ...

Imetelstat sustained red blood cell transfusion independence in patients with lower-risk myelodysplastic syndrome, with most ...

Kebriaei highlights the increasing use of measurable residual disease (MRD) as a key factor in determining the need for ...

Based Roundtable® event, Ian Krop, MD, PhD, and event participants discussed how different types of metastases and treatment ...

Findings from a subgroup analysis of the phase 3 LITESPARK-005 trial showed that belzutifan demonstrated superior efficacy ...

Reid W. Merryman, MD, discussed the latest developments with minimal residual disease assays in the management of patients ...

Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to leverage the immune system leading to significant improvements beyond the ...

The FDA has approved FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics to be used with olaparib, ...

Harnessing the power of the immune system has emerged as a key approach in addressing T-cell malignancies, with efforts to ...

Advances in follicular lymphoma treatment have included the development of novel immunotherapies in relapsed and refractory ...

Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, ...

Fianlimab plus cemiplimab was well-tolerated and showed durable responses, in pretreated patients with advanced clear cell ...